SOLID-TIMI 52 was a randomized, double-blind, placebo-controlled trial to assess the efficacy of darapladib, a novel Lp-PLA2 inhibitor, when added to standard of care in high-risk patients stabilized after ACS. MAIN RESULTS:Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trialJAMA. 2014 Sep 10;312(10):1006-15. PRESENTATIONS TIMI 52 … Continue reading SOLID-TIMI 52